* pregnant or breastfeeding * has underlying primary immunodeficiency * has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). * projected treatment is likely to involve plasma exchange * contraindication to receipt of sars-cov-2 vaccine * intolerance of or previous allergic reaction to tetanus vaccination * patients switching immunosuppressive therapies following enrolment with an absolute lymphocyte count \<0.5 x 109/l immediately prior to screening

* pregnant or breastfeeding * has underlying primary immunodeficiency * has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). * projected treatment is likely to involve plasma exchange * contraindication to receipt of sars-cov-2 vaccine * intolerance of or previous allergic reaction to tetanus vaccination * patients switching immunosuppressive therapies following enrolment with an absolute lymphocyte count \<0.5 x 109/l immediately prior to screening

* pregnant or breastfeeding * has underlying primary immunodeficiency * has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). * projected treatment is likely to involve plasma exchange * contraindication to receipt of sars-cov-2 vaccine * intolerance of or previous allergic reaction to tetanus vaccination.

* pregnant or breastfeeding * has underlying primary immunodeficiency * has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). * projected treatment is likely to involve plasma exchange * contraindication to receipt of sars-cov-2 vaccine * intolerance of or previous allergic reaction to tetanus vaccination.

pregnant or breastfeeding has underlying primary immunodeficiency has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). projected treatment is likely to involve plasma exchange contraindication to receipt of sars-cov-2 vaccine intolerance of or previous allergic reaction to tetanus vaccination.

pregnant or breastfeeding has underlying primary immunodeficiency has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). projected treatment is likely to involve plasma exchange contraindication to receipt of sars-cov-2 vaccine intolerance of or previous allergic reaction to tetanus vaccination.

pregnant or breastfeeding has underlying primary immunodeficiency has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). projected treatment is likely to involve plasma exchange contraindication to receipt of bnt162b2 vaccine intolerance of or previous allergic reaction to tetanus vaccination.

pregnant or breastfeeding has underlying primary immunodeficiency has received or likely to receive intravenous/subcutaneous immunoglobulin (ivig/scig). projected treatment is likely to involve plasma exchange contraindication to receipt of bnt162b2 vaccine intolerance of or previous allergic reaction to tetanus vaccination.